Fig. 3: Designed AAV_ITGs showed enhanced transduction in skeletal and cardiac muscles while strongly liver-detargeted in vivo.
From: An engineered AAV targeting integrin alpha V beta 6 presents improved myotropism across species
A Scheme of in vivo experiment. AAVs (CMV_GFP-Luciferase) were injected intravenously into 6wo C57BL6 mice at the dose of 1E13 vg/kg. Created with BioRender.com released under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license (https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en). B Representative images of the bioluminescence signal 20 days post-infection. C, D VCN (C) and gene expression (D) (GFP mRNA level in the liver and luciferase activity in other organs) for different AAVs in liver, skeletal muscles, heart, lung, and kidney (4 biological replicates, one-way ANOVA followed by FDR correction). Both designed AAV_ITGs strongly detargeted from the liver compared to AAV9, while they significantly improved VCN and luciferase activities over AAV9rh74 (and AAV9 with AAV9rh74_4um9 variant) in skeletal and cardiac muscles, and were detected and expressed at low levels in lung and kidney. Data in (C, D) are presented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns not significant. Source data are provided as a Source Data file.
